Thursday, March 28, 2024 11:36:13 AM
- an invitation at Thursday, March 28, 2024 9:03:22 AM for a webinar scheduled an hour later (Did I miss something?)
Topics will be:
- Company's mission and values
- Ethema is moving beyond the market noise to capture big returns in this underserved and underdeveloped sector.
- Our long-term capital appreciation growth strategy focuses on increased revenue per square foot at each facility in our portfolio
- Rising net collections month over month driven by our rollup strategy and technology advancements in billing and collections.
- Rising net collections month over month driven by our rollup strategy and technology advancements in billing and collections.
- Careful selection of choice property acquisitions with upside core asset values
Seriously, can anyone imagine a less than that content, for a company requiring CAPITAL and SERIOUS BUSINESS GROWTH
Fortunately we are in a business/market offering huge opportunities (market size to hit US$ 132.4 billion by 2027 with a growing CAGR of 5.3% since 2021).
At least for the last 3 years we seem to only have built a serious base to grow from. Quite an achievement considering where we restarted from.
This being said, Time has now come to do more than ''increased revenue per square foot''. We need serious investor(s) to:
- increase our revenues production space
- reduce our debt.
Being a '' team that is saving lives through addiction treatment.'' is nice but that team better start increasing of its impact by acquiring major capital rapidly. That MUST BE OUR STRATEGY now that we have a proven base to grow from. Any other objective would only let us survive for God only knows how long.
Patiently,
Roger
Recent GRST News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/07/2024 09:45:09 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 12/22/2023 09:54:23 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 12/22/2023 09:04:27 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:55:26 PM
- Form 1-A POS - • Edgar (US Regulatory) • 10/20/2023 07:29:40 PM
- Form 1-A POS - • Edgar (US Regulatory) • 08/29/2023 07:21:19 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/21/2023 08:37:36 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/14/2023 12:43:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/11/2023 04:51:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/18/2023 06:56:41 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM